Research programme: cochleate based therapeutics - Matinas Biopharma

Drug Profile

Research programme: cochleate based therapeutics - Matinas Biopharma

Alternative Names: Encochleated ibuprofen - Matinas BioPharma; Encochleated influenza vaccine - Matinas BioPharma; Encochleated siRNA; RNAi therapeutics

Latest Information Update: 02 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aquarius Biotechnologies
  • Developer Aquarius Biotechnologies; Matinas BioPharma; Rutgers
  • Class Catechols; Nonsteroidal anti-inflammatories; Omega 3 fatty acids; Phenylpropionates; Small interfering RNA; Small molecules; Vaccines
  • Mechanism of Action Cyclooxygenase inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inflammation; Influenza virus infections; Unspecified; Viral infections

Most Recent Events

  • 24 Apr 2017 Preclinical trials in Viral infections in USA (PO, IM)
  • 26 Oct 2016 Pharmacodynamics data from preclinical studies in Influenza virus infections presented at IDweek 2016
  • 26 Oct 2016 Preclinical trials in Influenza virus infections in USA (PO, Intranasal) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top